DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Esperion Therapeutics, Inc. (ESPR)
« Back to company indexESPR Chatter Timeline
Stock Ticker for ESPR
Most Active Tweeters for ESPR
| User | Tweets |
|---|---|
| @thefinreviewer | 8 |
| @reurope_stock | 8 |
| @bulletin_en | 6 |
| @1MinuteStock | 6 |
| @bibeypost_stock | 6 |
Recent Tweets for ESPR
 |
@AmericanBanking Esperion Therapeutics Inc $ESPR CEO Purchases $217,400.00 in Stock https://t.co/E7m9hopaS6 #stocks March 21st 2019, 5:03pm |
 |
@reurope_stock Esperion Therapeutics $ESPR Shareholder Bb Biotech Ag Increased Stake by $4.95 Million; Wedge Capital Management L… https://t.co/CjpLT4EedC March 21st 2019, 12:03pm |
 |
@ResearchPool $ESPR #Esperion Therapeutics Inc 1 director sold: A director at Esperion Therapeutics Inc sold 15,329 shares at 44.… https://t.co/Vq5bSI06ko March 21st 2019, 12:03pm |
 |
@TranscriptDaily Insider Selling: Esperion Therapeutics Inc $ESPR Director Sells 15,329 Shares of Stock https://t.co/t9IHQ7amzy March 21st 2019, 11:03am |
 |
@InsiderAlertsIA $ESPR: New Insider Filing on Director NICOLE VITULLO: https://t.co/DfXIs94IeC March 21st 2019, 11:03am |
 |
@bibeypost_stock Esperion Therapeutics, Inc. $ESPR Can't Be More Risky. The Stock Formed a Bearish H&S Chart Pattern https://t.co/0BjR7tJycb March 21st 2019, 10:03am |
|
@reurope_stock What Will Happen to Esperion Therapeutics, Inc. $ESPR Next? The Stock Formed a Several Months Bearish Head & Should… https://t.co/l0BGpsB3pq March 21st 2019, 10:03am |
 |
@insiderbuyings $ESPR new insider selling: 15329 shares. https://t.co/15l3VjMBP6 March 21st 2019, 10:03am |
 |
@ThisLincolnian Esperion Therapeutics $ESPR Trading Down 2.3% https://t.co/rhDYmzGdE1 March 20th 2019, 3:03pm |
 |
@EPeeps_Bot RT @EsperionInc: Team $ESPR is heading home from a productive #ACC19! We’re happy to have presented further validation of the potential pro… March 19th 2019, 4:03pm |
 |
@EsperionInc Team $ESPR is heading home from a productive #ACC19! We’re happy to have presented further validation of the potent… https://t.co/wp9JQtIHar March 19th 2019, 3:03pm |
 |
@BlogYomi Pl Capital Advisors Has Decreased Its Peoples Bancorp $PEBO Holding; Esperion Therapeutics $ESPR Sentiment Is 1 https://t.co/GwvPHHCoKm March 19th 2019, 3:03pm |
 |
@AniuStudent Yes, they do say they have no idea how $ESPR ’s cheap, oral med (without the typical statin side effects) will perf… https://t.co/TRnNFcx0iX March 19th 2019, 12:03pm |
|
@AniuStudent Thus, to repeat - What does $ESPR have that $AMRN doesn’t? A partner (for starters). ? March 19th 2019, 12:03pm |
|
@AniuStudent @Eminyel aka There are much larger problems that cardio pharmas have to deal with than $ESPR - w/ its established m… https://t.co/8cxOX0aPR1 March 19th 2019, 12:03pm |
 |
@AmpBioResearch @ByJonGardner Thanks for the helpful #ACC19 update. One clarification re: $ESPR, they are not going it alone at lea… https://t.co/Bb5sNtede3 March 19th 2019, 12:03pm |
 |
@AndrewHakkarai1 New results show benefits of Esperion’s cholesterol drug — but leave big questions unanswered https://t.co/Eb6mucJUg8 via @statnews $ESPR March 19th 2019, 11:03am |
 |
@Eminyel Can someone explain why $ESPR is at $46...seems strange after good news? March 19th 2019, 9:03am |
 |
@biotchart RT @HottestStockNow: $ESPR 's Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Late-Stage Study https://t.co/gl1w… March 19th 2019, 6:03am |
 |
@HottestStockNow $ESPR 's Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Late-Stage Study https://t.co/gl1wffxmpd March 19th 2019, 6:03am |
 |
@bulletin_en Esperion Therapeutics, Inc. $ESPR Trading at $48.53 after Decline https://t.co/U1WS3aq2fm March 18th 2019, 4:03pm |
|
@reurope_stock Esperion Therapeutics, Inc. $ESPR Just Recorded A Sigfniciant Decline https://t.co/eBSfBRXCw9 March 18th 2019, 3:03pm |
 |
@YuZhu4 RT @ByJonGardner: $ESPR and $AMRN bolster cases for approval, but the commercial questions linger. #ACC19 https://t.co/AwcKYL7vXt March 18th 2019, 3:03pm |
 |
@ByJonGardner $ESPR and $AMRN bolster cases for approval, but the commercial questions linger. #ACC19 https://t.co/AwcKYL7vXt March 18th 2019, 12:03pm |
 |
@dailypoliticaln Esperion Therapeutics $ESPR Stock Rating Reaffirmed by Chardan Capital https://t.co/nhmpljbudn March 18th 2019, 10:03am |
 |
@BioStocks $ESPR Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at #ACC19 https://t.co/5OeNYsrQxN March 18th 2019, 9:03am |
 |
@matthewherper New results show benefits of Esperion’s cholesterol drug — but leave big questions unanswered https://t.co/msiTbpLQOA $ESPR (paywall) #acc19 March 18th 2019, 9:03am |
 |
@thefinreviewer The Insider Target Biotech Purchases $2.49 million of Esperion Therapeutics, Inc. $ESPR; 3 Analysts Bullish Walker… https://t.co/U6stxEieWL March 18th 2019, 6:03am |
 |
@OlympiaReport Insider Buying: Esperion Therapeutics Inc $ESPR Major Shareholder Buys $2,494,500.00 in Stock https://t.co/OqFboZtzdL March 18th 2019, 4:03am |
|
@BlogYomi bluebird bio Inc. $ESPR Comparison side by side https://t.co/EtQ86Z6eF5 March 17th 2019, 11:03pm |
 |
@stocknewstimes Esperion Therapeutics Inc $ESPR CEO Purchases $243,650.00 in Stock https://t.co/geh7rXXdzx March 17th 2019, 12:03pm |
|
@TranscriptDaily Esperion Therapeutics Inc $ESPR CEO Purchases $243,650.00 in Stock https://t.co/eOTNiEokP2 March 17th 2019, 12:03pm |
|
@bibeypost_stock Esperion Therapeutics INC Ne $ESPR Holder Partner Fund Management LP Has Lowered Position as Share Price Declined https://t.co/MIrKjoo5TH March 17th 2019, 9:03am |
 |
@ConsumerFeed Esperion Therapeutics $ESPR Upgraded to “Neutral” at JPMorgan Chase & Co. https://t.co/FxADojATfn March 17th 2019, 8:03am |
 |
@bbnsnews Esperion Therapeutics $ESPR Upgraded to “Neutral” at JPMorgan Chase & Co. https://t.co/CSgPVvO5y7 March 17th 2019, 8:03am |
 |
@UlmHi Reviewing CollPlant Holdings Ltd. $ESPR's results https://t.co/NmONBvQ6DE March 17th 2019, 8:03am |
 |
@MarketChmln $ESPR upcoming event March 18: American College of Cardiology (ACC) Scientific Sessions & Expo. Options expiring on… https://t.co/QvVBvDxX6X March 17th 2019, 7:03am |
|
@bbnsnews Target N. V. Biotech Buys 50,000 Shares of Esperion Therapeutics Inc $ESPR Stock https://t.co/DT6X4M03dQ March 17th 2019, 5:03am |
|
@TranscriptDaily Esperion Therapeutics $ESPR Rating Increased to Neutral at JPMorgan Chase & Co. https://t.co/r18mOjP1sB March 16th 2019, 6:03pm |
 |
@ZolmaxNews Roger S. Newton Sells 25,000 Shares of Esperion Therapeutics Inc $ESPR Stock https://t.co/duyQZ7TBHi March 16th 2019, 6:03pm |
|
@thefinreviewer Esperion Therapeutics $ESPR Shareholder Sabby Management Has Lifted Its Stake; As https://t.co/MeFVwzGYx1 $AMZN Sto… https://t.co/XSIXdq6hX3 March 16th 2019, 5:03pm |
|
@OlympiaReport Esperion Therapeutics Inc $ESPR CEO Purchases $243,650.00 in Stock https://t.co/RybU8Psvw1 March 16th 2019, 4:03pm |
 |
@WatchlistN Insider Buying: Esperion Therapeutics Inc $ESPR Major Shareholder Buys 50,000 Shares of Stock https://t.co/ljvK3gTRgC March 16th 2019, 2:03pm |
 |
@registrarjourn Esperion Therapeutics $ESPR Given Hold Rating at Chardan Capital https://t.co/walVlj3Udw March 16th 2019, 5:03am |
 |
@EnterpriseLeade Esperion Therapeutics $ESPR Given Hold Rating at Chardan Capital https://t.co/4tZZgk70HH March 16th 2019, 5:03am |
|
@ThisLincolnian Esperion Therapeutics $ESPR Trading Down 8.5% After Insider Selling https://t.co/9RC7mDszM4 March 16th 2019, 3:03am |
|
@InsiderAlertsIA $ESPR: New Insider Filing on 10%+ Owner BIOTECH TARGET N V: https://t.co/p7CYpXeW7O March 15th 2019, 8:03pm |
 |
@TickerReport Target N. V. Biotech Purchases 50,000 Shares of Esperion Therapeutics Inc $ESPR Stock https://t.co/K6PAoWdQvQ March 15th 2019, 8:03pm |
|
@dailypoliticaln Target N. V. Biotech Buys 50,000 Shares of Esperion Therapeutics Inc $ESPR Stock https://t.co/U8qALsLuak March 15th 2019, 8:03pm |
 |
@ExecPicks Insider alert: Insider BIOTECH TARGET N V of $ESPR bought 50,000 shares @ $2,494,355.00 March 15th 2019, 7:03pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.